The normal structure and function of CD44 and its role in neoplasia

Journal of Clinical Pathology - Molecular Pathology

Volumn 51, Issue 4, 1998, Pages 191-200

  Sneath, R J S ^b   Mangham, D C ^a  

^a ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

CD44; Cellular adhesion; Metastasis; Tumorigenesis; Variant isoforms

Indexed keywords

HERMES ANTIGEN;

ANGIOGENESIS; ANTIGEN EXPRESSION; BREAST CARCINOMA; CARCINOGENESIS; CELL ADHESION; CELL INTERACTION; DIGESTIVE SYSTEM CANCER; HUMAN; LEUKEMIA; LYMPHOPOIESIS; MELANOMA; METASTASIS; MYELOPOIESIS; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN CONFORMATION; PROTEIN DETERMINATION; REVIEW; THYROID CARCINOMA; TISSUE DISTRIBUTION;

EID: 0031874645     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.51.4.191     Document Type: Review

References (114)

1. Stamenkovic I, Amiot M, Pesando J, et al. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989;56:1057-62.
2. Günthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastastic potential to rat carcinoma cells. Cell 1991;65:13-24.
3. Hughes E, Mencod G, Aucrust T. Murine cell surface glycoproteins. Characterization of a major component of 80,000 daltons as a polymorphic differentiation antigen of mesenchymal cells. J Biol Chem 1981;256:7023-7.
4. Trowbridge I, Lesley J, Schulte R, et al. Biochemical characterisation and cellular distribution of a polymorphic murine cell surface glycoprotein expressed on lymphoid tissues. Immunogenetics 1982;15:299-312.
5. Carter W, Wayner E. Characterisation of the class III collagen receptor, a phosphorylated transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 1988; 263:4193-201.
6. Gallatin W, Wayner E, Hoffman P, et al. Structural homology between lymphocyte receptors for high endothelium and class III extracellular matrix receptor. Proc Natl Acad Sci USA 1989;86:465-48.
7. Jalkanen S, Bargatze R, Herron L, et al. A lymphoid cell surface protein involved in endothelial recognition and lymphocyte homing in man. Eur J Immunol 1986;16:1195 202.
8. Haynes B, Telen M, Hale L, et al. CD44 - a molecule involved in leukocyte adherance and T-Cell activation. Immunol Today 1989;10:423-7.
9. Haynes B, Liao H, Patton K. The transmembrane hyaluronate receptor (CD44); multiple functions, multiple forms. Cancer Cells 1991;3:347-50.
10. Goodfellow PN, Banting G, Wiles MV, et al. The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2 is on human chromosome 11. Eur J Immunol 1982;12:659-63.
11. Hofmann M, Rudy W, Zoller M, et al. CD44 splice variants confer metastatic behaviour in rats: homologous sequences are expressed in human tumour cell lines. Cancer Res 1991; 51:5292-7.
12. Gallagher T. The protein and proteoglycan guises of Hermes CD44. Glycobiology 1992;2:93-7.
13. van Weering D, Baas P, Bos J. A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl 1994;3:100-6.
14. Hardingham T, Fosang A. Proteoglycans: many forms and many functions. FASEB J 1992;6:861-70
15. Brown T, Buouchard T, St John T, et al. Human keratino-cytes express a new CD44 core protein as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol 1991;113:207-21.
16. Idzerda R, Carter W, Nottenburg C, et al. Isolation and DNA sequence of a cDNA clone encoding a lymphocyte adhesion receptor for high endothelium. Proc Natl Acad Sci USA 1986;86:4659-63.
17. Goldstein L, Butcher E. Identification of mRNA that encodes an alternative form of H-CAM (CD44) in lymphoid and nonlymphoid tissues. Immunogenetics 1990; 32:389-97.
18. Underhill C. CD44: the hyaluronan receptor. J Cell Sci 1992;103:293-8.
19. Neame J, Isacke M. Phosphorylation of CD44 in vivo requires both Ser323 and Ser325, but does not regulate membrane localization or cytoskeleton interaction in epithelial cells. EMBO J 1992;11:4733-8.
20. Neame J, Isacke M. The cytoplasmic tail of CD44 is required for basolateral localization in epithelial MDCK cells but does not mediate association with the detergent-insoluble cytoskeleton of fibroblasts. J Cell Biol 1993;121: 1299-310.
21. Yang B, Yang BL, Savani RC, et al. Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CH44 and link protein. EMBO J 1994; 13:286-96.
22. Jalkanen S, Bargatze R, Herron L, et al. A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphcyte homing in man. Eur J Immunol 1986,16: 1195-202.
23. Couper D, Dougherty G, Harn H, et al. The complex CD44 transcnptional unit: alternative splicing of three internal exons generates the epithelial form of CD44. Biochem Biophys Res Common 1992;182:569-78.
24. Fox S, Fawcett J, Jackson D, et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994;54:4539-46.
25. Mackay C, Terpe H-J, Stauder R, et al. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82.
26. Sleeman J, Moll J, Sherman L, et al. The role of CD44 slice variants in human metastatic cancer. In: Cell adhesion and human disease. Chichester: Wiley, 1995:142-56.
27. Fox S, Gatter K, Jackson D, et al. CD44 and cancer screening. Lancet 1993;342:548-9.
28. Kugelman L, Ganguly S, Haggerty J, et al. The core protein of epican, a heparan sulfate proteoglycan on keratinocytes, is an alternative form of CD44. J Invest Dermatol 1992;99: 381-5.
29. Dall P, Hekele A, Ikenberg H. et al. Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis. Int J Cancer 1996;69:79-85.
30. Korabiowska M, Brinck C, Hönig J, et al. CD-44: a marker of metastases of head and neck melanomas. In Vivo 1995; 9:253-6.
31. Wirth K, Arch R, Somasundaram C, et al. Expression of CD44 isoforms carrying metastasis-associated seqences in newborn and adult rats. Eur J Cancer 1993;29A: 1172-7.
32. Yu Q, Toole B. Common pattern of CD44 isoforms is expressed in morphogenetically active epithelia. Dev Dyn 1997;208:1-10.
33. Shimizu Y, Seventer van G, Siraganian R, et al. Dual role of the CD44 molecule in T-cell adhesion and activation. J Immunol 1989;143:2457-63.
34. Huet S, Groux H, Caillou B, et al. CD44 contributes to T-cell activation. J Immunol 1989;143:798-801.
35. Conrad P, Rothman B, Kelley K, et al. Mechanism of peripheral T cell activation by coengagement of CD44 and CD44. J Immunol 1992;149:1833-9.
36. Arch R, Wirth, K, Holmann M, et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992;257:682-5.
37. Koopman G, Heider K-H, Horst E, et al. Activated human lymphocytes and aggressive non-Hodgkin lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 1993;177:897-904.
38. Jalkanen S, Bargatze R, DeLosToyes J, et al. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95 kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 1987;105:983-90.
39. Miyake K, Medina K, Hayashi S, et al. Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long term bone marrow cultures. J Exp Med 1990;171:477-88.
40. Kincade P. Molecular interactions between stromal cells and B lymphocyte precursors. Semin Immunol 1991;3:379-90.
41. Zöller M. CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J Mol Med 1995;73:425-38.
42. Trochon V, Mabilat C, Bertrand P, et al. Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer 1996;66: 664-8.
43. Webb D Shimizu Y, Seventer van G, et al. LFA-3, CD44, and CD45: physiological triggers of human monocyte TNF and IL-1 release. Science 990;249:1295-7.
44. Aruffo A, Stamenkovic I, Melnick M, et al. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-13.
45. Wayer E, Carter W. Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits. J Cell Biol 1987;105:1873-84.
46. Peach R, Hollenbaugh D, Stamenkovic I, et al. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol 1993;122:257-64.
47. Lesley J, Schulte R, Hyman R. Binding of hyaluronic acid to lymphoid cell lines is inhibited by monoclonal antibodies against Pgp-1. Exp Cell Res 1990;187:224-33.
48. Lesley J, He Q, Miyake K, et al. Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody. J Exp Med 1992;175:257-66.
49. Underhill C, Toole B. Physical characteristics of hyaluronate binding to the surface of simian virus 40 transformed 3T3 cells. J Biol Chem 1980;255:4544-9.
50. Lesley J, Kincade P, Hyman R. Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding of antibody. Eur J Immunol 1993;23:1902-9.
51. Underhill C. Interaction of hyaluronate with the surface of simian virus 40-transformed 3T3 cells: aggregation and binding studies. J Cell Sci 1982;56:177-89.
52. Stamenkovic I, Aruffo A, Amiot M, et al. The haematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 1991;10:343-8.
53. Bennett K, Modrell B, Greenfield B, et al. Regulation of CD44 binding to hyaluronan by glycosylation of variable spliced exons. J Cell Biol 1995;131:1623-33.
54. Katoh S, Zheng Z, Oritani K, et al. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J Exp Med 1995;182:419-29.
55. Lesley J, Hyman R. CD44 can be activated to function as an hyaluronic acid receptor in normal murine T cells. Eur J Immunol 1992;22:2719-23.
56. West D, Kumar S. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res 1989;183:179-96.
57. Lees V, Fan T, West D. Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccarides of hyaluronan. Lab Invest 1995;73:259-66.
58. Alho A, Underhill C. The hyaluronate receptor is preferentially expressed on proliferating epithelial cells. J Cell Biol 1989;108:1557-65.
59. Jain M, He Q, Lee W, et al. Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury. J Clin Invest 1996;97:596-603.
60. Faassen A, Schrager J, Klien D, et al. A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 1992;116:521-31.
61. Jalkanen S, Jalkanen M, Bargatze R, et al. Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man. J Immunol 1988;141: 1615-23.
62. Pessac B, Defendi V. Cell aggregation: role of acid mucopolysaccharides. Science 1972;175:898-900.
63. Green S, Tarone G, Underhill C. Aggregation of macrophages and fibroblasts is inhibited by a monoclonal. antibody to the hyaluronate receptor. Exp Cell Res 1988;178:224-32.
64. Underhill C, Dorfman A. The role of hyaluronic acid in intercellular adhesion of cultured mouse cells. Exp Cell Res 1978;117:155-64.
65. Underhill C, Toole B. Receptors for hyaluronate on the surface of parent and virus-transformed cell lines: binding and aggregation studies. Exp Cell Res 1981;131:419-23.
66. Underhill C, Green S, Comoglio P, et al. The hyaluronate receptor is identical to a glycoprotein of 85,000 Mr (gp85) as shown by a monoclonal antibody that interferes with binding activity. J Biol Chem 1987;262:13142-6.
67. Cooper D, Doughtery G. To metastasize or not? Selection of CD44 splice sites. Nat Med 1995;1:635-7.
68. Labarriere N, Pian J, Otry C, et al. H blood group antigen carried by CD44V modulates tumorigenicity of rat colon carcinoma cells. Cancer Res 1994;54:6275-81.
69. Bennett K, Jackson D, Simon J, et al. CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995;128:687-98.
70. Yanagishita M, Hascall V. Cell surface heparan sulfate proteoglycans. J Biol Chem 1992;267:9451-4.
71. Weber G, Ashkar S, Glimcher M, et al. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12.
72. Singh R, Patarca R, Schwartz J, et al. Definition of specific interaction between early-T-lymphocyte-activation-1 (eta-1) protein and murine macrophages in vitro and in vivo. J Exp Med 1990;171:1931-42.
73. Reinholt F, Hultenby K, Oldberg A, et al. Osteopontin - a possible anchor of osteoblasts to bone. Proc Natl Acad Sci USA 1990;87:4473-5.
74. Yue T, McKenna P, Ohlstein E, et al. Osteopontin-stimulated vascular smooth muscle cell is mediated by beta 3 integrin. Exp Cell Res 1994;214:459-64.
75. Guo Y, Ma J, Wang J, et al. Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res 1994;54:1561-5.
76. Hofmann M, Rudy W, Günthert U, et al. A link between ras and metastatic behaviour of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastases-specific variants of CD44 in CREF cells. Cancer Res 1993;53:1516-21.
77. Horst E, Meijer C, Radaszkiewicz T, et al. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 1990;4:595-9.
78. Zigmund S. Cell locomotion and chemotaxis. Curr Opin Cell Biol 1989;1:80-6.
79. Namec R, Toole B, Knudson T. The cell surface hyaluronate binding sites of invasive human bladder carcinoma cells. Biochem Biophys Res Commun 1987;149:249-57.
80. Bourguignon L, Lokeshwar V, Chen X, et al. Hyaluronic acid induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. J Immunol 1993;151:6634-44.
81. Culty M, Shirazi M, Thompson E, et al. Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. J Cell Physiol 1994;160:275-86.
82. Reber S, Matzku S, Güthert U. et al. Retardation of metastatic tumor growth after immunisation with metastasis-specific monoclonal antibodies. Int J Cancer 1990;46:919-27.
83. Seiter S, Arch R, Reber S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993;177:443-55.
84. Jiang W. In vitro models of cancer invasion and metastasis: recent developments. Eur J Surg Oncol 1994;20:493-9.
85. Zetter B. Adhesion molecules in tumor metastasis. Semin Cancer Biol 1993;4:219-29.
86. Zahalka M, Okon E, Gosslar U, et al. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J Immunol 1995;154:5345-55.
87. Heider K, Hofmann M, Horst E, et al. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993;120:227-33.
88. Hudson D, Speight P, Watt F. Altered expression of CD44 isoforms in squamous-cell carcinomas and cell lines derived from them. Int J Cancer 1996;66:457-63.
89. Salmi M, Grön-Virta K, Sointu P, et al. Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 1993;122:431-42.
90. Favrot M, Combaret V, Lasset C, et al. CD44 - a new prognostic marker for neuroblastoma. N Engl J Med 1993;329: 196.
91. Gao A, Lou W, Dong J-T, et al. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997;57:846-9.
92. Givehchian M, Woerner S, Lacroix J, et al. Expression of CD44 splice variants in normal respiratory epithelium and 11 bronchial carcinomas: no evidence for altered CD44 splicing in metastasis. Oncogene 1996;12:1137-44.
93. Higashikawa K, Yokozaki H, Ue T, et al. Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int J Cancer 1996;66:11-17.
94. Mayer B, Jauch K, Günthert U, et al. De-novo expression of CD44 and survival in gastric cancer. Lancet 1993;342: 1019-22.
95. Yamaguchi A, Saito M, Goi T, et al. Expression of CD44 variant exons 8-10 in gastric cancer. Jpn J Cancer Res 1995;86:1166-71.
96. Yamaguchi A, Urano T, Goi T, et al. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 1996;14:1122-7.
97. Takahashi K, Stamenkovic I, Cutler M, et al. CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene 1995;11: 2223-32.
98. Dämmrich J, Vollmers H, Heider K, et al. Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading. J Mol Med 1995;73:395-401.
99. Müller W, Schneiders A, Heider K-H, et al. Expression and prognostic value of the CD44 splicing variants vS and v6 in gastric cancer. J Pathol 1997;183:222-7.
100. Bartolazzi A, Peach R, Aruffo A, et al. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumour development. J Exp Med 1994;180;53-66.
101. Birch M, Mitchell S, Hart J. Isolation and characterisation of human melanoma cell variants expressing high and low level of CD-44. Cancer Res 1991;51:6660-7.
102. Danen E, Berge P, Muijen G, et al. Expression of CD44 and the pattern of CD44 alternative splicing in uveal melanoma. Melanoma Res 1996;6:31-5.
103. Friedrichs K, Franke F, Lisboa B-W, et al. CD44 isuforms correlate with cellular differentiation but not prognosis in human breast cancer. Cancer Res 1995;55:5424-33.
104. Sinn H-P Heider K-H, Skroch-Angel P, et al. Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Res Treat 1995;36:307-13.
105. Kaufmann M, Heider K-H, Sinn H-P, et al. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345:615-19.
106. Charpin C, Garcia S, Bouvier C, et al. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 1997;28:289-96.
107. Stevens J, Palechek P, Griebling T, et al. Expression of CD44 isoforms in human prostate tumor cell lines. Prostate 1996;28:153-61.
108. Rossi G, Marroni P, Paganuzzi M, et al. Increased serum levels of soluble CD44 standard, but not of variant isoforms vS and v6, in B cell chronic lymphocytic leukemia. Leukemia 1997;11:134-41.
109. Gansauge F, Gansauge S, Zobywalski A, et al. Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in the normal pancreas. Cancer Res 1995;55:5499-503.
110. Satoh K, Shimosegawa T, Koizumi M, et al. Expression of CD44 in duct cell carcinomas and in intraductal neoplasms of the pancreas. Anticancer Res 1997;17:215-20.
111. Ermak G, Jennings T, Robinson L, et al. Restricted patterns of CD44 variant expression in human papillary thyroid carcinoma. Cancer Res 1996;56:1037-42.
112. Shutz G, Tempfer C, Winkler S, et al. Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 1995;72:1494-7.
113. Wang H, DeYoung B, Swanson P, et al. CD44 immunoreactivity in soft-tissue sarcomas. Applied Immunohistochemistry 1996;4:184-9.
114. Sneath RJ, Mangham D, Sneath R. The pattern of CD44 expression and clinical outcome of synovial sarcomas. Acta Orthop Scand 1997;68(suppl 276):22.